CO5640094A2 - Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor - Google Patents

Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor

Info

Publication number
CO5640094A2
CO5640094A2 CO05119402A CO05119402A CO5640094A2 CO 5640094 A2 CO5640094 A2 CO 5640094A2 CO 05119402 A CO05119402 A CO 05119402A CO 05119402 A CO05119402 A CO 05119402A CO 5640094 A2 CO5640094 A2 CO 5640094A2
Authority
CO
Colombia
Prior art keywords
necrosis factor
tumor necrosis
alphus
pharmaceutical composition
composition including
Prior art date
Application number
CO05119402A
Other languages
English (en)
Spanish (es)
Inventor
Nigel Boughtonsmith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312321A external-priority patent/GB0312321D0/en
Priority claimed from SE0301655A external-priority patent/SE0301655D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5640094A2 publication Critical patent/CO5640094A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CO05119402A 2003-05-29 2005-11-24 Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor CO5640094A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312321A GB0312321D0 (en) 2003-05-29 2003-05-29 New combination
SE0301655A SE0301655D0 (sv) 2003-06-05 2003-06-05 New combination

Publications (1)

Publication Number Publication Date
CO5640094A2 true CO5640094A2 (es) 2006-05-31

Family

ID=33492248

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05119402A CO5640094A2 (es) 2003-05-29 2005-11-24 Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor

Country Status (15)

Country Link
US (1) US20070032465A1 (https=)
EP (1) EP1633401A1 (https=)
JP (1) JP2007501270A (https=)
KR (1) KR20060037258A (https=)
AR (1) AR044452A1 (https=)
BR (1) BRPI0410739A (https=)
CA (1) CA2526883A1 (https=)
CO (1) CO5640094A2 (https=)
IS (1) IS8188A (https=)
MX (1) MXPA05012705A (https=)
NO (1) NO20056131L (https=)
RU (1) RU2350354C2 (https=)
TW (1) TW200507829A (https=)
UY (1) UY28335A1 (https=)
WO (1) WO2004105798A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2006095355A1 (en) * 2005-03-07 2006-09-14 Ganga Raju Gokaraju Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
US9538710B2 (en) 2010-04-01 2017-01-10 Tony Wayne Covely Crop product tracking system and method
US10444122B2 (en) 2010-04-01 2019-10-15 Agri-Labs Holdings Llc Soil sample tracking system and method
CN103841969A (zh) * 2011-08-04 2014-06-04 美国卫生和人力服务部 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
EP0952832B1 (en) * 1996-05-20 2008-08-27 Darwin Discovery Limited Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CN1147483C (zh) * 1999-04-09 2004-04-28 阿斯特拉曾尼卡有限公司 金刚烷衍生物
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US8058441B2 (en) * 2001-07-02 2011-11-15 N.V. Organon Tetrahydroquinoline derivatives
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
KR20060037258A (ko) 2006-05-03
US20070032465A1 (en) 2007-02-08
CA2526883A1 (en) 2004-12-09
RU2005136131A (ru) 2006-07-27
WO2004105798A1 (en) 2004-12-09
IS8188A (is) 2005-12-20
AU2004243137A1 (en) 2004-12-09
AR044452A1 (es) 2005-09-14
MXPA05012705A (es) 2006-02-08
RU2350354C2 (ru) 2009-03-27
JP2007501270A (ja) 2007-01-25
UY28335A1 (es) 2004-12-31
TW200507829A (en) 2005-03-01
EP1633401A1 (en) 2006-03-15
BRPI0410739A (pt) 2006-06-27
NO20056131L (no) 2006-02-28

Similar Documents

Publication Publication Date Title
CO5640094A2 (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
AR025330A1 (es) Combinacion de sustancias activas con clonidina
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
UY28007A1 (es) Tratamiento terapeutico
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
AR041595A1 (es) Tratamiento terapeutico
EA200970353A1 (ru) Комбинированное лекарственное средство
UY27753A1 (es) Formulación farmacéutica que comprende melatonina.
UY29952A1 (es) Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
CA2385755A1 (en) Prevention of colorectal cancer
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
AR046955A1 (es) Preparacion efervescente de una sustancia basica farmaceuticamente activa
CL2004001262A1 (es) Composicion farmaceutica que comprende lamivudina, zidovudina y efavirenz, o derivados de ellos; kit farmaceutico; procedimiento para su preparacion; y uso en la preparacion de un medicamento para el tratamiento o prevencion de infecciones virales, e
AR011707A1 (es) Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento.
ECSP003314A (es) Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
AR039300A1 (es) Sistema para analisis de mercado de alimentos para animales
BR0311141A (pt) Interação sinergìstica de abacavir e alovudine

Legal Events

Date Code Title Description
FC Application refused